Episode
Advancing Off-the-Shelf CRISPR CAR-T Therapies into the Community Setting with Caribou Biosciences' Rachel Haurwitz
- Podcast
- Cell & Gene: The Podcast
- Published
- Jan 15, 2026
- Duration seconds
- 1172
- Processing state
not_requested
Actions
POST https://stenobird.com/v1/public/podcasts/cell-gene-the-podcast-4048431/episodes/advancing-off-the-shelf-crispr-car-t-therapies-into-the-community-setting-with-caribou-biosciences-rachel-haurwitz/transcription-requests
Idempotently request low-priority transcript generation for this episode.GET https://stenobird.com/podcast/cell-gene-the-podcast-4048431/advancing-off-the-shelf-crispr-car-t-therapies-into-the-community-setting-with-caribou-biosciences-rachel-haurwitz.md
Read the agent-friendly Markdown representation of this episode resource.
Summary
We love to hear from our listeners. Send us a message. Welcome to episode 120 of Cell & Gene: The Podcast. Host Erin Harris is joined by Rachel Haurwitz, CEO of Caribou Biosciences, to discuss the company’s progress in developing CRISPR-edited, off-the-shelf CAR-T therapies for hematologic malignancies. Their conversation centers on Vispacell, Caribou’s allogeneic CD19 CAR-T for second-line large B-cell lymphoma. Haurwitz explains how Caribou has systematically optimized its allogeneic pl...